Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer

Journal of Clinical Oncology

Volumn 14, Issue 10, 1996, Pages 2713-2721

  Holmes, F A ^a   Madden, T ^a   Newman, R A ^a   Valero, V ^a   Theriault, R L ^a   Fraschini, G ^a   Walters, R S ^a   Booser, D J ^a   Buzdar, A U ^a   Willey, J ^a   Hortobagyi, G N ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; PACLITAXEL;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG CLEARANCE; GRANULOCYTOPENIA; HUMAN; INFECTION RISK; INTRAVENOUS DRUG ADMINISTRATION; LEUKOCYTE COUNT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; STOMATITIS; TREATMENT PLANNING;

EID: 10144261886     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.10.2713     Document Type: Article

References (36)

1. Holmes FA, Walters RS, Theriault RL, et al: Phase II trial of Taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 83:1797-1805, 1991
2. Reichman BS, Seidman AD, Ownj PA, et al: Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer. J Clin Oncol 11:1943-1951, 1993
3. Holmes FA, Valero V, Walters RS, et al: The M.D. Anderson Cancer Center experience with Taxol in metastatic breast cancer. Monogr Natl Cancer Inst 15:161-170, 1993
4. Fisherman JS, McCabe M, Noone M, et al: Phase I study of Taxol, doxorubicin, plus granulocyte-colony stimulating factor in patients with metastatic breast cancer. J Clin Oncol 14:774-782, 1996
5. Zhan A, Rang Y-K, Regis J, et al: Taxol resistance: In vitro and in vivo studies in breast cancer and lymphomas. Proc Am Assoc Cancer Res 34:215, 1993 (abstr 1281)
6. Holmes FA, Frye D, Valero V, et al: Phase I study of Taxol and doxorubicin with G-CSF in patients without prior chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 11:60, 1992 (abstr 66)
7. Pestolazzi BC, Sotos GA, Choyke PL, et al: Typhlitis resulting from treatment with Taxol and doxorubicin in patients with metastatic breast cancer. Cancer 71:1797-1800, 1993
8. Holmes FA, Newman RA, Madden T, et al: Schedule dependent pharmacokinetics (PK) in a phase I trial of Taxol (T) and doxorubicin (D) as initial chemotherapy for metastatic breast cancer. Ann Oncol 5:197, 1994 (suppl 5, abstr 489)
9. Sledge GW, Goldstein RN, Sparano J, et al: Phase I trial of Adriamycin (A) + Taxol (T) in metastatic breast cancer (MBC). Eur J Cancer 29A:S81, 1993 (suppl 6, abstr 421)
10. Zubrod C, Schneiderman M, Frei E, et al: Appraisal of methods for the study of chemotherapy for cancer in man: Comparative therapeutic trial of nitrogen mustard and trimethylene thiophosphoramide. J Chronic Dis 11:7-33, 1960
11. Karnofsky DA, Abelman WH, Craver LF, et al: The use of nitrogen mustard in the palliative treatment of carcinoma. Cancer 2:634-656, 1948
12. Ajani JA, Welch SR, Raber MN, et al: Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 8:141-153, 1990
13. Robert J: Extraction of anthracyclines from biologic fluids for HPLC evaluation. J Liq Chromatogr 3:1561-1572, 1980
14. D'Argenio DZ, Schumitzky A: A program package for simulation and parameter estimation in pharmacokinetic systems. Comp Pro Biomed 9:115-134, 1979
15. Berg SL, Cowan KH, Balis FM, et al: Pharmacokinetics of Taxol and doxorubicin administered alone and in combination by continuous 72-hour infusion. J Natl Cancer Inst 86:143-145, 1994
16. Rowinsky EK, Gilbert MR, McGuire WP, et al: Sequences of Taxol and cisplatin: A phase I and pharmacologic study. J Clin Oncol 9:1692-1703, 1991
17. Kennedy MJ, Zahurak ML, Donehower R, et al: Phase I and pharmacologic study of sequences of paclitaxel and cyclophosphamide supported by granulocyte colony-stimulating factor in women with previously treated metastatic breast cancer. J Clin Oncol 14:783-791, 1996
18. Tolcher AW, Cowan KH, Noone MH, et al: Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients. J Clin Oncol 14:95-102, 1996
19. Liebmann JE, Fisher J, Teague D, et al: Sequence dependence of paclitaxel (Taxol) combined with cisplatin or alkylators in human cancer cells. Oncol Res 6:25-31, 1994
20. Gianni L, Munzone E, Capri G, et al: Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: High antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13:2688-2699
21. Von Hoff DD, Layard MW, Basa P, et al: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710-717, 1979
22. Praga C, Beretta G, Vigo P, et al: Adriamycin cardiotoxicity: A survey of 1,273 patients. Cancer Treat Rep 63:827-834, 1979
23. Legha SS, Benjamin RS, Mackay B, et al: Reduction of doxorubicin cardiotoxicity by prolonged intravenous infusion. Ann Intern Med 96:133-139, 1982
24. Hortobagyi GN, Frye D, Buzdar AU, et al: Decreased cardiac toxicity of doxorubicin administered by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 63:37-45, 1989
25. Madden T, Newman RA, Van NT: Sequence-dependent synergy of paclitaxel and doxorubicin in human breast carcinoma cells. Proc Am Assoc Cancer Res 36:359, 1995 (abstr 2139)
26. Webster LK, Millward MJ, Cosson EJ, et al: Cremophor EL changes the pharmacokinetics of doxorubicin. Proc Am Assoc Cancer Res 36:373, 1995 (abstr 2221)
27. Rowinsky EK: Clinical pharmacology of Taxol. Monogr Natl Cancer Inst 15:25-37, 1993
28. Gianni L: Theoretical and practical aspects of paclitaxel scheduling. Ann Oncol 6:861-863, 1995 (editorial)
29. Gianni L, Kearns CM, Giani A, et al: Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans. J Clin Oncol 13:180-190, 1995
30. Cresteil T, Monsarrat B, Alvinere P, et al: Taxol metabolism by human liver microsomes: Identification of cytochrome P450 isozymes involved in its biotransformation. Cancer Res 54:386-392, 1994
31. Smolen A, Anderson AD: Partial purification and characterization of a reduced nicotinamide adenine dinucleotide phosphate-linked aldehyde reductase from heart. Biochem Pharmacol 25:317-321, 1976
32. 3H]Taxol in the Sprague-Dawley rat. Drug Metab Dispos 22:254-258, 1994
33. Jamis-Dow CA, Klecker RW, Datki AG, et al: Metabolism of Taxol by human liver microsomes and effects of inhibitors. Proc Am Assoc Cancer Res 34:369, 1993 (abstr 2198)
34. Cusack BJ, Tesnohlidek DA, Loseke VL, et al: Effect of phenytoin on the pharmacokinetics of doxorubicin and doxorubicinol in the rabbit. Cancer Chemother Pharmacol 22:294-298, 1988
35. Madden T, Newman RA, Antoun G, et al: Paclitaxel effects on topoisomerase II transcription and activity in human breast cancer cell lines. Proc Am Assoc Cancer Res 37:358-359, 1996 (abstr 2446)
36. Husain SR, Rahman A: Mechanism of interaction of Taxol with p-glycoprotein in multidrug resistant cells. Proc Am Assoc Cancer Res 35:357, 1994 (abstr 2129)